Summary: For Contract Development and Manufacturing Organizations (CDMOs), transitioning to Biopharma 4.0 is crucial – the data and expertise amassed by these manufacturers represent an integral asset for their customers working to innovate in an increasingly competitive and fast-paced market.

Listen in as Mike and Darren share how new modalities and manufacturing technologies have altered the partnership landscape between developers and CDMOs.

Summary: In this webinar, we explore the drivers for process characterization and late-phase development including improving process understanding, enhancing robustness, and assurance that it delivers...

Summary: Process validation, including process characterization, is a critical step in the successful commercialization of a new biopharmaceutical on its path to commercialization. As the program approaches commercial launch...

Summary: In this article, experts detail how drug developers overcome obstacles that may complicate the launch of orphan drugs in order to meet their own needs and the needs of patients.

Summary: Catalent’s SMARTag platform technology offers ADC and biologics innovators a toolkit to develop optimized ADCs and bioconjugates.

Summary: The field’s top experts weigh in on the technologies they are working on, including self-amplifying RNA, computer-designed nanoparticles, expanding mRNA processes and...

Summary: During this panel discussion, executives share how their companies adapted to the challenges and what lessons they will take forward to ensure...

Summary: In December 2021, John Chiminski was featured on the expert panel of STAT’s "A Look Ahead at Biotech in 2022" event, which focused on the ongoing battle against the SARS-CoV-2 virus and explored what might be in store for the biotech industry in the years to come.

Summary: On December 13, 2021, EuropaBio hosted the final event of its 25th Anniversary programme with a focus on the story of mRNA.